Harrow Agrees To Buy Melt Pharmaceuticals

Harrow Inc. (HROW) has agreed to re-acquire its former subsidiary, Melt Pharmaceuticals, Inc., gaining full control of MELT-300, a patented sublingual formulation of midazolam and ketamine for rapid sedation and analgesia. MELT-300 reported positive, statistically superior results in its pivotal LOUISE Phase 3 trial in November 2024, with Harrow planning an NDA submission to the FDA in 2027 and targeting a U.S. launch in 2028, positioning the company for a significant pipeline expansion.

Analysis

Harrow Inc.'s (HROW) agreement to acquire its former subsidiary, Melt Pharmaceuticals, represents a strategic consolidation of a high-potential, late-stage asset. The core of the deal is MELT-300, a patented sublingual formulation for procedural sedation that has been significantly de-risked following positive topline results from its pivotal LOUISE Phase 3 trial. The trial demonstrated that MELT-300 was statistically superior to both a key active component (midazolam) and a placebo, a crucial milestone for its regulatory pathway. Harrow has outlined a clear, albeit long-term, timeline, with a New Drug Application (NDA) submission planned for 2027 and a potential U.S. launch in 2028. While the undisclosed financial terms of the acquisition introduce uncertainty regarding the immediate balance sheet impact, the move secures full ownership of a promising future revenue stream and reinforces Harrow's growth narrative by expanding its pipeline beyond its core ophthalmics focus.

Key Decisions for Investors

• Investors should view this acquisition as a significant positive for Harrow's long-term growth profile, adding a de-risked asset with a clear path to market, though material revenue is not expected until at least 2028.
• The primary catalysts to monitor are future clinical updates and progress towards the 2027 NDA submission, as any deviation from this timeline will directly impact the asset's valuation and the company's stock performance.
• Given that financial terms were not disclosed, it is prudent to scrutinize upcoming financial filings for details on the acquisition's cost and its impact on Harrow's cash position and balance sheet.